Age-stratified burden of pneumococcal community acquired pneumonia in hospitalised Canadian adults from 2010 to 2015

BACKGROUND: In Canada, 13-valent pneumococcal conjugate vaccine (PCV13) is recommended in childhood, in individuals at high risk of invasive pneumococcal disease (IPD) and in healthy adults aged ≥65 years for protection against vaccine-type IPD and pneumococcal community-acquired pneumonia (pCAP). S...

Descripción completa

Detalles Bibliográficos
Autores principales: LeBlanc, Jason, ElSherif, May, Ye, Lingyun, MacKinnon-Cameron, Donna, Ambrose, Ardith, Hatchette, Todd F, Lang, Amanda LS, Gillis, Hayley D, Martin, Irene, Demczuk, Walter H, LaFerriere, Craig, Andrew, Melissa K, Boivin, Guy, Bowie, William, Green, Karen, Johnstone, Jennie, Loeb, Mark, McCarthy, Anne, McGeer, Allison, Semret, Makeda, Trottier, Sylvie, Valiquette, Louis, Webster, Duncan, McNeil, Shelly A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Respiratory Epidemiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078693/
https://www.ncbi.nlm.nih.gov/pubmed/32188585
http://dx.doi.org/10.1136/bmjresp-2019-000550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7078693/
https://www.ncbi.nlm.nih.gov/pubmed/32188585
http://dx.doi.org/10.1136/bmjresp-2019-000550

Ejemplares similares